U.S. Biotech Stock News

If you are wondering whether Globalstar's share price still makes sense after a big run, or if expectations are getting ahead of reality, this article breaks down what the current price could imply about its underlying value. Globalstar closed at US$62.79, with returns of 5.1% over the last week, a 1.4% decline over the last month, a 1.9% decline year to date, and gains of 125.1% over 1 year, 217.1% over 3 years, and 237.6% over 5 years. These moves have put Globalstar on more investors'...

A Montana federal judge has allowed a PFAS related class-action lawsuit against DuPont de Nemours (DD) and other manufacturers to proceed, keeping potential RICO and multi state claims in play for now. See our latest analysis for DuPont de Nemours. The latest legal setback arrives after a sharp 45.47% decline in DuPont de Nemours' 90 day share price return, even as its 1 year total shareholder return of 38.25% and 3 year total shareholder return of 51.40% reflect a stronger longer term...

Unusual Machines (UMAC) is back in focus after announcing a new US$2.1 million purchase order for domestically assembled drone systems serving defense and government customers, with fulfillment planned across the first half of the year. See our latest analysis for Unusual Machines. The purchase order lands on top of a sharp recent move in the shares, with a 30 day share price return of 87.74% and a 1 year total shareholder return of 29.62%. This suggests momentum has been building into the...

Earlier this month, The Vita Coco Company appointed veteran retail executive Shelley Broader as a Class II director, adding more than 25 years of global leadership experience across mass and specialty retail, grocery, and consumer brands to its board. On the marketing front, Vita Coco is also extending its partnership with U.S. Men’s National Team star Weston McKennie as Global Brand Ambassador, aligning the brand with a high-profile athlete as soccer’s biggest international tournament comes...

Earlier in January 2026, Bruker’s Energy & Supercon Technologies (BEST) division announced two expanded multi-year superconductor supply agreements for MRI magnets, with a combined expected value of about US$500 million and durations including one contract extending up to seven years. By deepening long-term relationships with global radiology manufacturers and supporting helium-free MRI architectures, BEST is reinforcing Bruker’s role in enabling next-generation medical imaging and wider...

In January 2026, Xenon Pharmaceuticals presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining clinical and regulatory plans for its lead epilepsy candidate azetukalner, including expected Phase 3 data in March 2026 and an NDA filing target in the second half of 2026. A distinctive aspect of the update was Xenon’s emphasis on azetukalner’s broader potential, with ongoing Phase 3 programs extending into neuropsychiatric indications such as major depressive disorder, where...

Semtech (SMTC) is back in focus after a strong Q3, with 12.8% year on year revenue growth and earnings ahead of analyst expectations, alongside sector tailwinds linked to AI driven semiconductor demand. See our latest analysis for Semtech. Sustained interest in AI related semiconductors has helped Semtech’s share price, which now trades at US$77.26 after a 4.15% 1 day share price return and a 13.99% 90 day share price return. Its 3 year total shareholder return of about 15x contrasts with a...

Whirlpool (WHR) has come back onto investors’ radars after its recent share price move, with the stock up around 12% over the past month and roughly 16% in the past 3 months. See our latest analysis for Whirlpool. That recent momentum, including a 12.1% 30 day share price return and 16.5% 90 day share price return, contrasts with Whirlpool’s 30.1% 1 year total shareholder return loss. As a result, short term optimism is building off a weaker longer term track record. If Whirlpool’s move has...

Salesforce (CRM) is back in focus after recent share price pressure, with the stock showing negative returns over the past week, month, past 3 months and year. That has some investors reassessing what they are paying for its growth profile. See our latest analysis for Salesforce. At a share price of $233.53, Salesforce has seen pressure build recently, with a 7 day share price return of 10.36% and a 1 year total shareholder return of 26.55% decline, even though the 3 year total shareholder...

Interactive Brokers announced in January 2026 that eligible IB LLC clients can now fund their brokerage accounts with stablecoins like USDC, enabling near-instant, 24/7 deposits that are automatically converted to US dollars with no deposit fee from the broker and a 0.30% conversion fee from zerohash. This move directly tackles long-standing cross-border funding frictions for international investors, potentially making Interactive Brokers more attractive to globally active and...

First Interstate BancSystem recently reported mixed quarterly results, with flat year-on-year revenue, an earnings-per-share beat, and a shortfall in net interest income versus analyst expectations. While management underscored its long-term plan around organic growth and tighter cost control, some analysts highlighted weakening revenue trends and projected net interest income declines as potential constraints on future profitability. We’ll now explore how these mixed results, particularly...

In recent days, Bank of New York Mellon Corporation reported record fourth-quarter 2025 net income of US$1,461 million and earnings per share ahead of expectations, alongside Board approval of a US$0.53 common dividend and multiple preferred dividends. The company paired these results with new medium-term financial targets and fresh fixed-income offerings totaling about US$1.55 billion, underscoring its push to fund technology, AI and digital asset initiatives while continuing substantial...

NeoGenomics, Inc. recently announced a planned Chief Financial Officer transition, with industry veteran Abhishek Jain set to assume the CFO role on March 2, 2026, following preliminary unaudited 2025 revenue of about US$190 million for the fourth quarter and US$727 million for the full year. This combination of leadership change and double‑digit revenue growth guidance raises questions about how NeoGenomics will balance financial discipline with its expansion in oncology diagnostics. Next,...

If you are wondering whether Independence Realty Trust is attractively priced or not, you are in the right place to get a clear view of what the current share price might be implying. The stock closed at US$17.08 recently, with returns of a 2.3% decline over 7 days, 0.6% over 30 days, a 3.0% decline year to date, a 6.8% decline over 1 year, 7.8% over 3 years and 48.0% over 5 years. Taken together, this gives you a mixed picture of short-term softness and longer-term gains. Recent coverage of...

Caledonia Mining (NYSEAM:CMCL) is drawing attention after upsizing its convertible senior notes offering to US$125 million to help fund the Bilboes gold project, and it has also reported 2025 Blanket Mine production in line with guidance. See our latest analysis for Caledonia Mining. The sharp 16.9% one day share price decline and softer 7 day move come after a period where the 30 day share price return is 11.8%, while the 1 year total shareholder return is very large at almost 3x. This...

Recent performance snapshot for Nutanix (NTNX) With no single headline event setting the tone, Nutanix (NTNX) has been drawing attention for its recent share performance, including a last close of $48.67 and mixed short and longer term total returns. See our latest analysis for Nutanix. Recent trading has been choppy, with a 1 day share price return of a 5.38% decline and a 7 day share price return of an 8.36% decline. The 1 year total shareholder return of a 26.87% decline contrasts with an...

Nuvation Bio (NUVB) is back in focus after signing an exclusive license and collaboration agreement with Eisai for taletrectinib, bringing immediate cash payments and potential milestones tied to global expansion beyond its existing markets. See our latest analysis for Nuvation Bio. Despite the Eisai agreement and recent conference visibility, Nuvation Bio’s share price return has seen a 27.34% fall over the past week and a 29.10% decline over the past month. At the same time, the 90 day...

Recent commentary from Oakmark Funds and several Wall Street firms has put fresh attention on CDW (CDW), as institutions highlight its evolution into a full-service IT solutions provider with expanding exposure to software, services, cybersecurity, and generative AI. See our latest analysis for CDW. At a share price of $132.29, CDW has seen a 30 day share price return of 8.78% decline and a 90 day share price return of 13.22% decline, while its 1 year total shareholder return of 28.49%...

Board changes arrive as Arbor Realty Trust (ABR) works through credit pressures Arbor Realty Trust (ABR) is juggling borrower delinquencies, weaker net interest income, and dividend pressure just as a long-tenured director retires and a new Class II director joins the board. See our latest analysis for Arbor Realty Trust. Against the backdrop of dividend cuts, refinancing challenges on 2021 and 2022 loans, and these board changes, Arbor Realty Trust’s 7 day share price return of 5.39%...

AiRWA stock overview after recent performance swing AiRWA (YYAI) has drawn attention after a sharp share price move, with a gain of about 61% over the past month, in contrast to a 76% decline over the past 3 months. See our latest analysis for AiRWA. At a latest share price of $1.46, AiRWA’s 60.58% 30 day share price return and 62.04% year to date share price return sit against a 97.19% 1 year total shareholder return decline. This suggests that recent momentum has picked up after a much...

In recent days, Barclays raised its rating on EastGroup Properties to a more favorable level, joining several other firms that have upgraded the REIT and refreshed their research views. This cluster of analyst upgrades points to a shift in professional sentiment, with research coverage increasingly emphasizing EastGroup’s operating outlook and business positioning. Next, we’ll examine how this broader wave of analyst upgrades might influence EastGroup’s existing investment narrative around...

Sunoco (SUN) has put fresh numbers on the table for 2026, issuing adjusted EBITDA guidance of $3.1b to $3.3b, built around Parkland acquisition synergies and an ongoing bolt-on acquisition program. See our latest analysis for Sunoco. Sunoco’s adjusted EBITDA outlook and ongoing acquisitions are landing at a time when momentum in the units has been firm, with a 10.11% 30 day share price return and a 5 year total shareholder return of 168.34% suggesting long term holders have already seen...

Why Virtus Investment Partners Is On Investors’ Radar Today Virtus Investment Partners (VRTS) has recently drawn attention after a period of mixed share performance, with a small gain over the past month alongside weaker moves over the past 3 months and year. At a last close of $170.27, the US based asset manager sits against a backdrop of measured value indicators, including a value score of 3 and an intrinsic discount figure provided by some models of 19.24%. See our latest analysis for...

On 12 January 2026, Booz Allen Hamilton announced a new collaboration with Andreessen Horowitz, becoming the first-ever a16z Technology Acceleration Partner for Governments to help bring portfolio companies’ AI, autonomy, and electronic warfare solutions into secure U.S. government environments. This relationship links a16z’s growth-stage tech ecosystem with Booz Allen’s mission-focused AI, cybersecurity, and engineering capabilities to co-develop deployable solutions and commercial IP for...